Liquidia (LQDA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
19 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, welcoming all virtual participants and outlining the virtual-only format, enabling remote voting and Q&A participation.
The agenda and Rules of Conduct were posted online, detailing procedures for voting and submitting questions.
Technical and legal formalities were addressed to ensure the meeting was duly authorized.
Board and executive committee updates
Directors and executive officers were introduced, including those present and absent.
The independent registered public accounting firm, PricewaterhouseCoopers, was introduced.
Shareholder proposals
Three proposals were presented: election of Class 2 directors, ratification of the accounting firm, and advisory approval of executive compensation.
Latest events from Liquidia
- Q2 2026 net income hit $74.7M as YUTREPIA sales and market share surged, but litigation risks persist.LQDA
Q2 2026 - YUTREPIA's robust launch and market expansion drive confidence in growth and profitability.LQDA
Wells Fargo 20th Annual Healthcare Conference 2025 - YUTREPIA's rapid growth and pipeline expansion drive strong revenue and market leadership.LQDA
Jefferies Global Healthcare Conference 2026 - YUTREPIA's strong launch and expanding pipeline drive growth and innovation in PAH and PH-ILD.LQDA
H.C. Wainwright 4th Annual BioConnect Investor Conference - YUTREPIA's rapid growth and innovation position it to capture a $1B+ market by 2027.LQDA
Bank of America Global Healthcare Conference 2026 - Rapid growth and profitability in 2025 set a clear path to $1B revenue by 2027.LQDA
Q4 2025 - Yutrepia and L606 advance inhaled treprostinil therapy with strong data and regulatory progress.LQDA
R&D Day 2025 - FDA-approved YUTREPIA launches with strong clinical data, broad access, and rapid commercialization.LQDA
Status Update - Yutrepia is set for 2025 launch with strong clinical, regulatory, and financial positioning.LQDA
43rd Annual J.P. Morgan Healthcare Conference 2025